Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
about
ChannelopathiesFollicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal ModelsNeuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Aquaporin-4 positive neuromyelitis optica spectrum disorders secondary to thrombopenic purpura: A case report.Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaRetinal glycoprotein enrichment by concanavalin a enabled identification of novel membrane autoantigen synaptotagmin-1 in equine recurrent uveitisSignificant Association Between Fc Receptor-Like 3 Polymorphisms (-1901A>G and -658C>T) and Neuromyelitis Optica (NMO) Susceptibility in the Chinese Population.Brain abnormalities in neuromyelitis optica spectrum disorder.Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disordersThe cancer drug tamoxifen: a potential therapeutic treatment for spinal cord injury.Monitoring neuromyelitis optica activity.Glial influence on the blood brain barrier.ASTROCYTES: EMERGING STARS IN LEUKODYSTROPHY PATHOGENESIS.Targeting ion channels for the treatment of autoimmune neuroinflammation.Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases.Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies.Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.The complement and immunoglobulin levels in NMO patients.Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party.Stratification of astrocytes in healthy and diseased brain.Blood Brain Barrier Permeability Could Be a Biomarker to Predict Severity of Neuromyelitis Optica Spectrum Disorders: A Retrospective Analysis
P2860
Q24601791-824F0BE5-E695-4FD4-AAF0-57ABBB60E4C0Q26795577-B4FAE681-4162-48C4-A76A-A9B5098013D9Q30576477-262FF155-7BCE-481B-AA63-37C20D6AE5F7Q30785267-6FB82F83-468A-4550-9C06-01D77000A1FBQ33438341-B601755C-0A76-42A0-AA5B-CEBE916F300DQ34338762-94BE698C-374C-4455-A8AA-38BFFB8B20D3Q34510602-1DC7563D-556A-4C09-A181-7D141934AD14Q35540930-F5D8493D-6434-4CA6-8233-A06E5B408C93Q36457932-A8DD60B0-A2E7-46DD-8538-77054155E1A0Q37059594-639AEF1E-1429-41E9-B4C2-8466B5B89DA5Q37523956-52FF6C47-78BC-40CF-BBCB-366C28CFBD3AQ38140020-47A4AA23-9E3A-4C93-B267-C18B087C6FEBQ38152380-FE29BF2E-8E57-45F0-81F3-8BA95B42CEB5Q38171484-785E38E1-311B-4C37-8201-5B222374BE32Q39357037-17BC43A1-57F5-4CB4-BCE7-8E18BD0672B4Q39785941-49866DAA-4224-42A8-8763-ADE846940F53Q40425520-F29AC3E0-04ED-4FE1-8547-0A0C5B45BC8CQ41818298-93AFD81E-24D1-4907-B7E7-5E218683473CQ41831300-980295CF-699F-474F-8723-D78974FE29A4Q44177350-266C5993-D0FC-44AB-AE38-A67392459E76Q45867293-64DE91E1-5595-4396-9760-599A35EDF97AQ46321594-FD272F7E-21DA-4801-9BDA-9C14C462A746Q58797276-8C99280B-A6DB-4303-B72D-F7A2D26BD26F
P2860
Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
@en
type
label
Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
@en
prefLabel
Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
@en
P2860
P1476
Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
@en
P2093
A S Verkman
Julien Ratelade
P2860
P304
P356
10.1016/J.BIOCEL.2012.06.013
P577
2012-06-17T00:00:00Z